Indonesia Next Generation Sequencing Market Size, Share, Trends & Forecast Analysis

The Indonesia next generation sequencing market is projected to reach $275.39 million by 2036, at a CAGR of 13.8% from 2026 to 2036, up from an estimated $75.60 million in 2026. The market was valued at $66.30 million in 2025, with government-funded genomics programmes representing an important source of sequencing demand in the country. The growth of this market is primarily fueled by the scale and continuity of Indonesia's national genomics programme, rising cancer burden and growing demand for molecular testing, and the exceptional genetic diversity of the Indonesian population. Additionally, expansion of sequencing into agricultural and aquaculture applications, development of domestic bioinformatics and data analysis capabilities, and Government Regulation 28 of 2024's requirement that health data be stored and processed within Indonesian jurisdiction are expected to create substantial growth opportunities for market participants.

Indonesia's national genomics programme, the Biomedical and Genome Science Initiative (BGSi), has expanded the country's installed sequencing base from approximately 12 machines to around 60 machines, with the Ministry of Health adding 48 whole genome sequencing machines across national referral hospitals. Ten Ministry of Health vertical hospitals coordinate the national genomics programme alongside ten specialised genomics centres, and a laboratory network supported by the United Nations Development Programme extends to 29 established laboratories. The Ministry of Health has set an objective of sequencing 400,000 human genomes by 2030. According to IARC estimates, Indonesia recorded more than 400,000 new cancer cases in 2022, and within the market, oncology is expected to register the highest growth among major clinical applications, at a CAGR of 14.8% during the forecast period.

The key players operating in the Indonesia next generation sequencing market are MGI Tech Co., Ltd. (China), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), BGI Genomics Co., Ltd. (China), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China).

The Indonesia next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.

Among all the offerings, the Sequencing segment is expected to account for the largest share of the market in 2026, supported by continued investment in sequencing infrastructure and the expansion of the national genomics programme. Data Analysis and Bioinformatics is expected to register the highest growth during the forecast period as the volume of genomic data generated in Indonesia continues to increase.

Among all the applications, Research and Other Applications are expected to account for the largest share of the market in 2026, reflecting the strong role of government-funded genomics and research programmes. Clinical Applications are expected to continue expanding as next generation sequencing gains importance in oncology, reproductive health, infectious diseases, and rare diseases.

Among all the end users, Hospitals, Clinical and Reference Laboratories are expected to account for the largest share of the market in 2026, supported by the expansion of sequencing capabilities within major healthcare institutions and the role of hospitals in delivering national genomics programmes. Academic and Research Institutes also represent an important source of demand, while Pharmaceutical and Biotechnology Companies are expected to increase their use of sequencing technologies for drug discovery and precision medicine.

Key Questions Answered in the Report:

What is the current revenue generated by the Indonesia next generation sequencing market?
At what rate is the Indonesia next generation sequencing market demand projected to grow through 2036?
What are the historical market sizes and growth rates of the Indonesia next generation sequencing market?
What are the major factors driving the growth of this market? What are the major restraints affecting the market?
Which segments in terms of offering, application, and end user are expected to create major traction for the manufacturers in this market?
Who are the major players in the Indonesia next generation sequencing market? What are their specific product offerings in this market?
What are the recent strategic developments in the Indonesia next generation sequencing market? What are the impacts of these strategic developments on the market?

1. Market Definition & Scope

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.1.1. Bottom Up Approach
2.3.1.2. Top Down Approach
2.3.2. Growth Forecast Approach
2.3.3. Assumptions for the Study

3. Executive Summary

3.1. Introduction
3.2. Market Dynamics
3.3. Segmental Analysis
3.3.1. By Offering
3.3.2. By Application
3.3.3. By End User
3.4. Competitive Landscape

4. Market Insights

4.1. Overview
4.2. Indonesia Healthcare & Genomics Landscape
4.3. National Genomics & Precision Medicine Initiatives
4.3.1. National Biomedical & Genomics Research Programs
4.3.2. Precision Medicine & Cancer Genomics Initiatives
4.3.3. Infectious Disease Genomic Surveillance Programs
4.4. Factors Affecting Market Growth
4.4.1. Drivers
4.4.1.1. Scale and Continuity of the National Genomics Programme
4.4.1.2. Rising Cancer Burden and Its Weight Within National Insurance Spending
4.4.1.3. Exceptional Genetic Diversity of the Indonesian Population
4.4.1.4. Health Data Residency Directing Sequencing into Domestic Facilities
4.4.2. Restraints
4.4.2.1. Exclusion of Genomic Diagnostics from the Insurance Benefit Package
4.4.2.2. Shortage of Personnel Trained in Clinical Genomics
4.4.2.3. Geographic Dispersion of Demand Across an Archipelagic Country
4.4.3. Challenges
4.4.3.1. Limited Depth of Accredited Laboratory Capacity Outside Principal Centres
4.4.3.2. The Single Licence Holder Rule Constrains Channel Strategy
4.4.3.3. Regulatory Uncertainty Under an Unsupervised Data Protection Framework
4.4.4. Trends
4.4.4.1. Migration of Sequencing and Analysis into Domestic Facilities
4.4.4.2. Extension of Sequencing into Agricultural and Aquaculture Applications
4.4.4.3. Competition on Workflow Cost in Programme Procurement
4.4.4.4. Consolidation of the Workflow by Leading Suppliers
4.5. Indonesia NGS Market: Regulatory Analysis
4.5.1. Introduction
4.5.2. Medical Device Regulations
4.5.3. Laboratory Accreditation & Clinical Testing Regulations
4.5.4. Import & Distribution Regulations
4.5.5. Data Privacy & Genomic Data Regulations
4.6. Reimbursement Landscape
4.7. Case Studies/Use Cases
4.8. Porter's Five Forces Analysis
4.8.1. Bargaining Power of Buyers
4.8.2. Bargaining Power of Suppliers
4.8.3. Threat of Substitutes
4.8.4. Threat of New Entrants
4.8.5. Degree of Competition

5. Indonesia NGS Market Assessment, By Offering

5.1. Overview
5.2. Sample Preparation
5.2.1. Kits & Reagents
5.2.2. NGS Workstations
5.3. Sequencing
5.3.1. NGS Systems
5.3.2. Consumables
5.3.3. Services
5.4. Data Analysis/Bioinformatics
5.4.1. Software
5.4.2. NGS Informatics Services
5.5. Commercial Sequencing/Outsourced Services
5.5.1. Whole Genome Sequencing Services
5.5.2. Whole Exome Sequencing Services
5.5.3. Targeted Sequencing Services
5.5.4. RNA Sequencing Services
5.5.5. Other Commercial Sequencing Services

6. Indonesia NGS Market Assessment, By Application

6.1. Overview
6.2. Research & Other Applications
6.2.1. Drug Discovery
6.2.2. Agriculture & Animal Research
6.2.3. Other Applications
6.3. Clinical Applications
6.3.1. Oncology
6.3.2. Reproductive Health
6.3.3. Infectious Diseases
6.3.4. Rare Diseases
6.3.5. Other Clinical Applications

7. Indonesia NGS Market Assessment, By End User

7.1. Overview
7.2. Pharmaceutical & Biotechnology Companies
7.3. Hospitals, Clinical & Reference Laboratories
7.4. Academic & Research Institutes
7.5. Other End Users

8. 8. Competitive Landscape

8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
8.4.1. Industry Leaders
8.4.2. Market Differentiators
8.4.3. Vanguards
8.4.4. Emerging Companies
8.5. Market Share/Ranking by Key Players
8.5.1. MGI Tech Co., Ltd. (China)
8.5.2. Illumina, Inc. (U.S.)
8.5.3. Thermo Fisher Scientific Inc. (U.S.)
8.5.4. QIAGEN N.V. (Netherlands)
8.5.5. BGI Genomics Co., Ltd. (China)

9. Company Profiles

9.1. Illumina, Inc.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Portfolio
9.1.4. Strategic Developments
9.1.5. SWOT Analysis
9.2. Thermo Fisher Scientific Inc.
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Portfolio
9.2.4. Strategic Developments
9.2.5. SWOT Analysis
9.3. QIAGEN N.V.
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Portfolio
9.3.4. Strategic Developments
9.3.5. SWOT Analysis
9.4. Agilent Technologies, Inc.
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Portfolio
9.4.4. Strategic Developments
9.4.5. SWOT Analysis
9.5. F. Hoffmann La Roche Ltd.
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Portfolio
9.5.4. Strategic Developments
9.5.5. SWOT Analysis
9.6. Revvity, Inc.
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Portfolio
9.6.4. Strategic Developments
9.6.5. SWOT Analysis
9.7. Pacific Biosciences of California, Inc.
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Portfolio
9.7.4. Strategic Developments
9.7.5. SWOT Analysis
9.8. Danaher Corporation
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Portfolio
9.8.4. Strategic Developments
9.8.5. SWOT Analysis
9.9. Oxford Nanopore Technologies plc
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Portfolio
9.9.4. Strategic Developments
9.9.5. SWOT Analysis
9.10. MGI Tech Co., Ltd.
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Portfolio
9.10.4. Strategic Developments
9.11. BGI Genomics Co., Ltd.
9.11.1. Company Overview
9.11.2. Financial Overview
9.11.3. Product Portfolio
9.11.4. Strategic Developments
9.11.5. SWOT Analysis
9.12. Eurofins Scientific SE
9.12.1. Company Overview
9.12.2. Financial Overview
9.12.3. Product Portfolio
9.12.4. Strategic Developments
9.12.5. SWOT Analysis
9.13. Novogene Co., Ltd.
9.13.1. Company Overview
9.13.2. Financial Overview
9.13.3. Product Portfolio
9.13.4. Strategic Developments

10. Appendix

10.1. Available Customization
10.2. Questions Answered in This Report
10.3. About Meticulous Research

LIST OF TABLES

Table 1. Indonesia NGS Market, By Offering, 2024-2036 (Usd Million)
Table 2. Indonesia NGS Sample Preparation Market, By Type, 2024-2036 (Usd Million)
Table 3. Indonesia NGS Sequencing Market, By Type, 2024-2036 (Usd Million)
Table 4. Indonesia NGS Data Analysis Market, By Type, 2024-2036 (Usd Million)
Table 5. Indonesia Commercial Sequencing Services Market, By Type, 2024-2036 (Usd Million)
Table 6. Indonesia NGS Market, By Application, 2024-2036 (Usd Million)
Table 7. Indonesia NGS Research & Other Applications Market, By Type, 2024-2036 (Usd Million)
Table 8. Indonesia NGS Clinical Applications Market, By Type, 2024-2036 (Usd Million)
Table 9. Indonesia NGS Market, By End User, 2024-2036 (Usd Million)
Table 10. Competitive Dashboard: Indonesia NGS Market

LIST OF FIGURES

Figure 1. Indonesia NGS Market Ecosystem
Figure 2. Key Stakeholders In The Indonesia NGS Market
Figure 3. Research Process
Figure 4. Key Secondary Sources Referenced For This Study
Figure 5. Primary Research Techniques
Figure 6. Key Executives Interviewed
Figure 7. Breakdown Of Primary Interviews (Supply-Side & Demand-Side)
Figure 8. Market Sizing And Growth Forecast
Figure 9. Key FindiNGS: The Indonesia NGS Opportunity
Figure 10. Indonesia NGS Market: Drivers, Restraints And Opportunities At A Glance
Figure 11. Indonesia NGS Market: Segmental Analysis
Figure 12. Indonesia NGS Market, By Offering, 2026 Vs. 2036 (Usd Million)
Figure 13. Indonesia NGS Market, By Application, 2026 Vs. 2036 (Usd Million)
Figure 14. Indonesia NGS Market, By End User, 2026 Vs. 2036 (Usd Million)
Figure 15. Indonesia NGS Market: Key Market Insights
Figure 16. Indonesia: Healthcare And Genomics Landscape
Figure 17. Indonesia: Cancer Burden And National Insurance Cost
Figure 18. Indonesia: Bgsi National Genomics Programme
Figure 19. Indonesia: Precision Medicine And Cancer Genomics
Figure 20. Impact Analysis Of Market Dynamics
Figure 21. Indonesia: Growth Of The Installed Sequencing Base
Figure 22. Indonesia: Cancer Incidence And Projected Growth
Figure 23. Indonesia: The Coverage Gap In Genomic Diagnostics
Figure 24. Indonesia: Regulatory Framework Governing Sequencing
Figure 25. Indonesia: Medical Device Registration Pathway
Figure 26. Indonesia: Data Protection Framework
Figure 27. Indonesia: Jkn Coverage And Cancer Claim Cost
Figure 28. Indonesia: Sequencing Use Cases
Figure 29. Porter's Five Forces Analysis
Figure 30. Indonesia NGS Market, By Offering, 2026 Vs. 2036 (Usd Million)
Figure 31. Sample Preparation: Market Size and CAGR, 2024-2036
Figure 32. Kits & Reagents: Market Size and CAGR, 2024-2036
Figure 33. NGS Workstations: Market Size and CAGR, 2024-2036
Figure 34. Sequencing: Market Size and CAGR, 2024-2036
Figure 35. NGS Systems: Market Size and CAGR, 2024-2036
Figure 36. Consumables: Market Size and CAGR, 2024-2036
Figure 37. Sequencing Services: Market Size and CAGR, 2024-2036
Figure 38. Indonesia: From Sequence To Clinical Decision
Figure 39. Software: Market Size and CAGR, 2024-2036
Figure 40. NGS Informatics Services: Market Size and CAGR, 2024-2036
Figure 41. Indonesia: In-Country Versus Cross-Border Sequencing
Figure 42. Whole Genome Sequencing Services: Market Size and CAGR, 2024-2036
Figure 43. Whole Exome Sequencing Services: Market Size and CAGR, 2024-2036
Figure 44. Targeted Sequencing Services: Market Size and CAGR, 2024-2036
Figure 45. Rna Sequencing Services: Market Size and CAGR, 2024-2036
Figure 46. Other Commercial Sequencing Services: Market Size and CAGR, 2024-2036
Figure 47. Indonesia NGS Market, By Application, 2026 Vs. 2036 (Usd Million)
Figure 48. Research & Other Applications: Market Size and CAGR, 2024-2036
Figure 49. Drug Discovery: Market Size and CAGR, 2024-2036
Figure 50. Agriculture & Animal Research: Market Size and CAGR, 2024-2036
Figure 51. Other Applications: Market Size and CAGR, 2024-2036
Figure 52. Indonesia: Clinical Sequencing By Funding Route
Figure 53. Clinical Applications: Market Size and CAGR, 2024-2036
Figure 54. Indonesia: Cancer Burden and Molecular Testing Demand
Figure 55. Oncology: Market Size and CAGR, 2024-2036
Figure 56. Reproductive Health: Market Size and CAGR, 2024-2036
Figure 57. Infectious Diseases: Market Size and CAGR, 2024-2036
Figure 58. Rare Diseases: Market Size and CAGR, 2024-2036
Figure 59. Other Clinical Applications: Market Size and CAGR, 2024-2036
Figure 60. Indonesia NGS Market, By End User, 2026 Vs. 2036 (Usd Million)
Figure 61. Pharmaceutical & Biotechnology Companies: Market Size and CAGR, 2024-2036
Figure 62. Indonesia: Hospital and Laboratory Capability
Figure 63. Hospitals, Clinical & Reference Laboratories: Market Size and CAGR, 2024-2036
Figure 64. Indonesia: Research Institutional Landscape
Figure 65. Academic & Research Institutes: Market Size and CAGR, 2024-2036
Figure 66. Other End Users: Market Size and CAGR, 2024-2036
Figure 67. Indonesia NGS Market: Competitive Structure
Figure 68. Key Growth Strategies Adopted By Leading Players, 2023-2026
Figure 69. Indonesia NGS Market: Competitive Benchmarking
Figure 70. Indonesia NGS Market: Share/Ranking Analysis By Key Players, 2025
Figure 71. Illumina, Inc.: Financial Snapshot
Figure 72. Illumina, Inc.: SWOT Analysis
Figure 73. Thermo Fisher Scientific Inc.: Financial Snapshot
Figure 74. Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 75. Qiagen N.V.: Financial Snapshot
Figure 76. Qiagen N.V.: SWOT Analysis
Figure 77. Agilent Technologies, Inc.: Financial Snapshot
Figure 78. Agilent Technologies, Inc.: SWOT Analysis
Figure 79. F. Hoffmann-La Roche Ltd.: Financial Snapshot
Figure 80. F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 81. Revvity, Inc.: Financial Snapshot
Figure 82. Revvity, Inc.: SWOT Analysis
Figure 83. Pacific Biosciences of California, Inc.: Financial Snapshot
Figure 84. Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 85. Danaher Corporation: Financial Snapshot
Figure 86. Danaher Corporation: SWOT Analysis
Figure 87. Oxford Nanopore Technologies Plc: Financial Snapshot
Figure 88. Oxford Nanopore Technologies Plc: SWOT Analysis
Figure 89. Mgi Tech Co., Ltd.: SWOT Analysis
Figure 90. Mgi Tech Co., Ltd.: Financial Snapshot
Figure 91. Bgi Genomics Co., Ltd.: SWOT Analysis
Figure 92. Bgi Genomics Co., Ltd.: Financial Snapshot
Figure 93. Eurofins Scientific Se: SWOT Analysis
Figure 94. Eurofins Scientific Se: Financial Snapshot
Figure 95. Novogene Co., Ltd.: SWOT Analysis
Figure 96. Novogene Co., Ltd.: Financial Snapshot

Companies Mentioned

MGI Tech Co., Ltd.
Illumina, Inc.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
BGI Genomics Co., Ltd.
Agilent Technologies, Inc.
F. Hoffmann La Roche Ltd.
Revvity, Inc.
Pacific Biosciences of California, Inc.
Danaher Corporation
Oxford Nanopore Technologies plc
Eurofins Scientific SE
Novogene Co., Ltd. (China).

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€3848EUR$4,175USD£3,242GBP
1 - 5 USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a 1-5 user license, allowing up to five users have access to the product.	€5415EUR$5,875USD£4,562GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€7259EUR$7,875USD£6,115GBP

Indonesia Next Generation Sequencing Market Size, Share, Trends & Forecast Analysis - Forecast to 2036

Key Questions Answered in the Report:

Table of Contents

Companies Mentioned

Key Questions Answered in the Report:

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Philippines Next-Generation Sequencing (NGS) Market Size, Share, Trends & Forecast Analysis - Forecast to 2036

Malaysia Next Generation Sequencing Market Size, Share, Trends & Forecast Analysis - Forecast to 2036

Next Generation Sequencing (NGS) Industry Outlook - Opportunity Analysis and Industry Forecast (2026-2036)

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends & Forecast Analysis - Forecast to 2036

Vietnam Next-Generation Sequencing (NGS) Market Size, Share, and Trend Analysis - Forecast to 2036